John Cox - 25 Mar 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
Chief Executive Officer and President, Director
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol
DYN
Transactions as of
25 Mar 2024
Net transactions value
$0
Form type
4
Filing time
27 Mar 2024, 16:24:10 UTC
Previous filing
11 Aug 2023
Next filing
04 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock Option (Right to Buy) Award $0 +679,853 $0.000000 679,853 25 Mar 2024 Common Stock 679,853 $26.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on March 25, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 25, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service

Remarks:

Chief Executive Officer and President